{"nctId":"NCT01100502","briefTitle":"A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)","startDateStruct":{"date":"2010-04-30","type":"ACTUAL"},"conditions":["Disease, Hodgkin"],"count":329,"armGroups":[{"label":"Brentuximab vedotin","type":"EXPERIMENTAL","interventionNames":["Drug: brentuximab vedotin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"brentuximab vedotin","otherNames":["SGN-35","Adcetris"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with HL who have received ASCT in the previous 30-45 days\n* Patients at high risk of residual HL post ASCT\n* Histologically-confirmed HL\n* ECOG of 0 or 1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Previous treatment with brentuximab vedotin\n* Previously received an allogeneic transplant\n* Patients who were determined to have a best clinical response of progressive disease with salvage treatment immediately prior to ASCT\n* History of another primary malignancy that has not been in remission for at least 3 years\n* Post ASCT or current therapy with other systemic anti-neoplastic or investigational agents","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival by Independent Review","description":"Time from date of randomization to the first documentation of disease progression by independent review or to death due to any cause, whichever comes first","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"24.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Time from date of randomization to date of death due to any cause","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Adverse Events or Laboratory Abnormalities","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"163","spread":null},{"groupId":"OG001","value":"142","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"147","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Anti-therapeutic Antibodies (ATA) to Brentuximab Vedotin","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138","spread":null},{"groupId":"OG001","value":"142","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":160},"commonTop":["Peripheral sensory neuropathy","Upper respiratory tract infection","Neutropenia","Fatigue","Cough"]}}}